ArticleKidney3602026
Hospitalization and Emergency Department Costs in Patiromer and Sodium Zirconium Cyclosilicate Users.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
key pointsThis study shows a statistically significant 15% potential heart failure hospitalization and edema event cost savings among patiromer users. Annual costs were $52,153 in the sodium zirconium cyclosilicate cohort and $44,245 in the patiromer cohort, an annual difference of $7908 per person. In addition to clinical benefits, these results highlight financial implications for health plans, value-based care organizations, and patients.
backgroundA previous study using US electronic health records directly compared the risk of heart failure-related or edema-related hospitalizations and edema-related emergency department (ED) visits for hyperkalemic patients using patiromer or sodium zirconium cyclosilicate. Incidence rates for all three clinical outcomes favored patiromer, but the previous study did not capture costs.
methodsThe current investigation combines the patiromer and sodium zirconium cyclosilicate cohort heart failure hospitalization and edema event rates from the previous study with mean event and prescription costs from 2019 to 2021 Optum Clinformatics data. The resulting heart failure-related and edema-related event and medication costs were then compared between patiromer and sodium zirconium cyclosilicate cohorts. We inflation-adjusted those to 2024 US dollars.
resultsFor patiromer, costs for heart failure hospitalizations, edema hospitalizations, and edema ED visits were $30,269.05, $2520.13, and $31.67 per person-year, respectively. For sodium zirconium cyclosilicate, costs for heart failure hospitalizations, edema hospitalizations, and edema ED visits were $39,478.29, $4061.48, and $51.04, respectively. Medication costs per person-year were $11,423.68 and $8561.71 for patiromer and sodium zirconium cyclosilicate, respectively. The aggregated cost savings with patiromer was $7907.99 per person-year (95% confidence interval, $5453.58 to $10,362.40) for all heart failure hospitalization and edema hospitalization and ED events, adjusted for both inflation and medication costs.
conclusionsTotal event and medication costs were $44,245 in the patiromer cohort and $52,153 in the sodium zirconium cyclosilicate cohort. The $7908 difference represents a 15% (95% confidence interval, 10% to 20%) cost savings associated with patiromer from all events, including medication costs and adjusted for inflation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.